Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GS-248

            Therapeutic Area: Dermatology Product Name: GS-248

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hadean Ventures

            Deal Size: $21.1 million Upfront Cash: Undisclosed

            Deal Type: Financing July 07, 2020


            The investment enables Gesynta to fund continued development of lead candidate GS-248 in systemic sclerosis patients.